The Journal of Immunology, Vol 147, Issue 3 927-932, Copyright © 1991 by American Association of Immunologists

ARTICLES

A covalent dimer of complement C4b serves as a subunit of a novel C5 convertase that involves no C3 derivatives

T Masaki, M Matsumoto, R Yasuda, RP Levine, H Kitamura and T Seya
Department of Immunology, Center for Adult Diseases, Osaka, Japan.

A C intermediate, LAC14, was prepared from TNP-aminocaproyl liposomes sensitized with anti-TNP antibody (Ab) and purified human C1 and C4. LAC14, containing radiolabeled C4, was analyzed by SDS-PAGE followed by autoradiography, and yielded a 210-kDa band and a predominant 400-kDa band. The 210-kDa band consisted of monomeric C4b bound to low molecular mass acceptors. The 400-kDa band was comprised of a 200-kDa moiety, as well as beta- and gamma-chains of C4. The 200-kDa moiety contained neither C1 nor sensitizing Ab, but it was largely decreased by treatment with NH2OH to the 90-kDa moiety with the mobility corresponding to the alpha'-chain of C4b. A covalent dimer of C4b, therefore, is the predominant form of C4b deposited on liposomes sensitized with antibody. The C4b-C4b dimer formed rapidly (within 5 min) followed by slow dissociation into monomers. The LAC14 bearing the C4b dimer but not the monomer was lysed, although with relatively low efficiency, by the addition of oxyC2 and EDTA-supplemented C3-deficient serum (C3DS), and, furthermore, LAC142 possessed the ability to convert C5 into C5a and C5b. Moreover, lysis was inhibited not by anti-C3 Ab but by anti-C4 Ab. In other experiments, the dimer served as an element of C3 convertase, as well. These findings imply that the C4b dimer, when complexed with C2, expresses C3/C5 convertase activity without participation of C3, and may provide a molecular mechanism whereby sera from patients with complete C3 deficiency retain the ability to induce C-mediated cytolysis.

This article has been cited by other articles:

				M. Krych-Goldberg, R. E. Hauhart, T. Porzukowiak, and J. P. Atkinson Synergy between Two Active Sites of Human Complement Receptor Type 1 (CD35) in Complement Regulation: Implications for the Structure of the Classical Pathway C3 Convertase and Generation of More Potent Inhibitors J. Immunol., October 1, 2005; 175(7): 4528 - 4535. [Abstract] [Full Text] [PDF]

				N. Rawal and M. K. Pangburn Formation of High Affinity C5 Convertase of the Classical Pathway of Complement J. Biol. Chem., October 3, 2003; 278(40): 38476 - 38483. [Abstract] [Full Text] [PDF]

				U. Baumann, N. Chouchakova, B. Gewecke, J. Kohl, M. C. Carroll, R. E. Schmidt, and J. E. Gessner Distinct Tissue Site-Specific Requirements of Mast Cells and Complement Components C3/C5a Receptor in IgG Immune Complex-Induced Injury of Skin and Lung J. Immunol., July 15, 2001; 167(2): 1022 - 1027. [Abstract] [Full Text] [PDF]

				N. Rawal and M. K. Pangburn Formation of High-Affinity C5 Convertases of the Alternative Pathway of Complement J. Immunol., February 15, 2001; 166(4): 2635 - 2642. [Abstract] [Full Text] [PDF]

				N. Rawal and M. K. Pangburn C5 Convertase of the Alternative Pathway of Complement. KINETIC ANALYSIS OF THE FREE AND SURFACE-BOUND FORMS OF THE ENZYME J. Biol. Chem., July 3, 1998; 273(27): 16828 - 16835. [Abstract] [Full Text] [PDF]